Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × INDUSTRY × ribociclib × Clear all

Phase

Status

Recruiting 30 Completed 30 Active not recruiting 13 Terminated 11 Not yet recruiting 2 Withdrawn 1 Available 1

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Paclitaxel 31 Cyclophosphamide 30 Cisplatin 29 Carboplatin 27 Bevacizumab 27 Fluorouracil 24 pembrolizumab 21 Nivolumab 21 Leucovorin 20 Rituximab 19 avelumab 18 Gemcitabine 18 Docetaxel 18 Dexamethasone 18 Capecitabine 17 130-nm albumin-bound paclitaxel 14 ALT-803 13 Oxaliplatin 12 Cetuximab 12 fludarabine 11 Ipilimumab 11 venetoclax 10 atezolizumab 10 Radiosurgery 10 Radiotherapy 9 Pemetrexed 9 Omacor 9 Lenalidomide 9 Bendamustine Hydrochloride 9 yeast-CEA vaccine 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03081234 2018-03-15

EarLEE-2

Novartis

Phase 3 Withdrawn

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡